University Lille1 (UL1) – France
Lead Partner of the AMPTEC cluster

Contact: Prof. F. Affouard
+33 (0)3 20 43 68 15

The Lead Partner (University Lille1, Unité Matériaux Et Transformations) is composed of two teams:

The Molecular Therapeutical Materials team (coordinator of IDEA) is one of the very few groups of physicists working at the frontier of materials and pharmaceutical science. Activities focus on the physical state of molecular compounds under various kinds of stresses: temperature, pressure, grinding and dehydration. The work has direct implications in the control of the formulation and stability of drugs. The team collaborates with pharmaceutical and agrochemical compagnies (Sanofi, Astra-Zenecca, Roquette). The LP possesses a strong experience in national and european research projects: ANR BIOSTAB, ANR Mi-Pha-Sol , PRIM, IFMAS, INTERREG IVA IDEA (Lead Partner).

The Polymeric Systems Engineering team (partner of Multides, responsible: Prof. B. Martel) is specialised in the synthesis of cyclodextrin polymers and in the functionalization of implantable devices with cyclodextrins widely used in the pharmaceutical domain for its complexing and solubilizing properties towards drugs and is applied as as a drug vector.

University of Cambridge - UK
Contact: Prof. W. Jones
01223 336468

The Chancellor, Masters and Scholars of the University of Cambridge
The Old Schools, Trinity Lane

The Chemistry Department at the Univeristy of Cambridge is one of the UK’s major academic departments with expertise in various areas related to medicinal and pharmaceutical materials. It hosts the Unilever Centre for Chemical Informatics dealing with numerous aspects of drug structure and efficacy, it is a partner in the Pfizer Institute of Pharmaceutical Materials based in Cambridge (provides the Deputy Director of the Institute), it has collaborative projects with the Cambridge Crystallographic Data Centre (a database used by all the world’s major pharmaceutical companies) and has support from the UK EPSRC, MRC and charities such as Leverhulme Foundation as well as the EU. Cluster members work on projects with numerous pharmaceutical companies either directly or through consortia.

University Lille2 (UL2) – France
Controlled Drud Delivery Systems and Biomaterials
Contact: Prof. J. Siepmann
+33 (0)3 20 96 47 08

Université Lille 2 Droit et Santé
42, rue Paul Duez
59800 LILLE

The Controlled Drud Delivery Systems and Biomaterials team is specialized in the field of controlled drug delivery systems and biomaterials. It develops innovative strategies using novel types of advanced drug delivery systems and biomaterials allowing for an accurate control of the resulting drug release kinetics. It is involved in various regional, national and international research projects and research clusters:the Pharmaceutical Solid State Research Cluster (PSSRC), the ANR BIOSTAB, the ANR ACROHNEM , the Prim platform, the EU BCDDS, the FRI-Biovalo the FRI-J’innove the FRI-Endotis the Fondation Recherche Médical the NIH R21 , the EuroTransBio the OSEO LICAPO , the INTERREG IDEA , and the INTERREG MultiDES projects. The Controlled Drud Delivery Systems and Biomaterials team is also extensively collaborating with industrial partners: Merck, Bayer, BASF, FMC BioPolymer, Meggle, Gattefossé, Minakem, Astra-Zeneca, ImaBiotech, Roquette, Ethypharm, Pérouse Médical, Cousin Biotech, Bone & Joint Research, and Neurelec.

University of Ghent – Belgium
Contact: Prof. C. Vervaet
+ 32 9 264 80 69

Universiteit Gent
Harelbekestraat 72
9000 GENT
Belgium Flanders

The team is specialised in the development of innovative pharmaceutical dosage forms, using specific combinations of excipients and/or manufacturing techniques. The research team has extensive experience in hot-melt extrusion, spray drying, granulation and tableting as manufacturing techniques, and has state-of-the-art equipment within its research facilities at Ghent University for the manufacturing as well as the fundamental characterisation of the novel dosage forms.

The team is involved in several national and international research projects, collaborating with academic partners as well as with pharmaceutical companies (focusing on innovator and generic drugs). The team is participating in regionally funded projects in collaboration with Seps Pharma (see below) and is a partner of the Pharmaceutical Solid State Research Cluster. The team has extensive experience in the valorisation of its research results via the licensing of several patents to pharmaceutical companies.

University of East Anglia (UEA) - UK
Contact : Dr Sheng Qi
+44 (0) 1603592925

University of East Anglia
Earlham Road
NR4 7TJ Norwich UK

UEA is represented by the School of Pharmacy which was founded in 2003. The school has a unique blend of expertise in micro- and nano-scale characterisation of pharmaceutical interactions and molecular level studies of drug-biomaterials interactions. The state-of-art facilities include scanning probe based imaging analysis, MRI, a full range of NMR facilities, thermal analysis suite, X-ray diffraction, SEM, TEM, animal facility and human tissue bank. The research output of the School has direct impact, providing practical applications for the research in the areas of pharmaceutical formulations design and product/excipient physical stability on storage as well as in biological fluids. The School has built long term working relationships with pharmaceutical and excipient companies such as Evonik, Novartis, Merck Serono, and Bristol-Myers Squibb. The School is currently hosting projects sponsored by BBSRC, MRC, RSC, and various charity funding bodies.

SEPS Pharma – Belgium
Contact: Dr Y. Gonissen
+32 (0)9 261 69 03

SEPS Pharma
Technologiepark 4
9052 GENT
Belgium Flanders

SEPS Pharma is a privately held pharmaceutical company engaged in drug delivery and development. The SEPS Pharma group provides advanced drug product development services to the leading pharmaceutical and biotechnology companies and is dedicated to the development of innovative drug delivery systems serving solutions to enhance bioavailability and control drug release.

The group offers a full suite of drug development services encompassing preclinical development, preformulation development, formulation development, analytical development, dosage forms development, scaling-up and clinical trial manufacturing of small molecules and biopharmaceuticals for oral, pulmonary, nasal and parenteral delivery. The company is dedicated to the development of innovative drug delivery systems serving solutions to enhance bioavailability and control drug release for difficult-to-formulate drug candidates.

University of Greenwich – UK

Contact: Dr. D. Douroumis
+44 208 331 8440

University of Greenwich
Medway Campus, Central Avenue, Chatham Maritime
ME4 4TB Chatham UK

The UoG has extensive experience in continuous processing and manufacturing technologies such as hot melt extrusion, spray-drying high-pressure homogenization and jet dispensing. It has also excellent analytical facilities (e.g. X-ray, DSC, HSM, NMR, SE, TEM, etc.) with highly specialized technicians. The Centre of Innovation in Process Engineering and Research (CIPER) is a part of UoG sponsored by Thermo Scientific (Germany). It has been awarded various projects from EPSCR, TEMPUS and INTERREG while posses links with small and large pharmaceutical companies. The UoG was the lead partner in the MultiDES project in collaboration with the Universities of Lille 1&2.

The Nutrition Health Longevity Cluster (NHL) – France
Contact: Julie Lefebvre
+33 (0)3 28 55 90 60

Pôle Nutrition Santé Longévité
Nutrition Health Longevity cluster
Parc Eurasanté Ouest, 310 Avenue Eugène Avinée
59120 LOOS

The Nutrition Health Longevity (NHL) Cluster exists to foster ambitious, joint research projects in the Nord-Pas de Calais region, with a view to making the region’s industries more competitive.It was certified as a Competitiveness Cluster by the French Government in July 2005 and aims to become one of the top three innovators in Europe in the field of health and nutrition, by fostering collaboration on innovative research projects in the fields of cardiovascular and metabolic diseases, age-related neurodegenerative diseases and nutrition. As a hub for new medical, scientific and industrial strategies, NHL has become a key player in forging links between private and public research players in its specialist fields.

Core development themes:

Protecting human health and wellbeing through nutrition:

- Functional foods and ingredients

- Improving the nutritional quality of food products

Diagnosis and treatment of cardiovascular and metabolic diseases and neurodegenerative diseases

Previous page: Conference
Next page: Associated Partners